REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2021 >

Decisions 14th December 2021

At the meeting on the 14th December, the following decisions were agreed


New Drug Requests 


Faecal Microbiota Transplant (TLS Red)

  • For treatment of recurrent C. difficile infection.

Guanfacine (TLS Red) 

  • For treatment of ADHD in adults where stimulants are not suitable, not tolerated or ineffective as a 4th line option after atomoxetine.

Trazodone (TLS Blue)

  • For treatment of anxiety and depression.

Bevespi Aerosphere 

  • For COPD as an additional option for patients who prefer to use a pMDI device and are unable to use other inhaler devices due to the nature of their lung function, breathing technique, or dexterity concerns.


TLS Status Changes

Vancomycin oral capsules 

  • Vancomycin oral capsules for C. diff changed from TLS Blue to TLS Green.


  • Aripiprazole for adults changed from TLS Amber 3 months to TLS Amber No SCP.


  • Pilocarpine from TLS Blue to TLS Amber No SCP.


Other Formulary Decisions

Plenvu® (TLS Green) - to be included in the BNSSG Adult Joint Formulary as an alternative to MoviPrep®.

Link to the AWP Med 37 guide - 'Physical health monitoring for psychotropic medicines' to be included in the BNSSG Formulary to support antidepressant and antipsychotic monitoring in primary care.

Hydroxychloroquine monitoring advice 'concise sheet' to be removed.


Further Work

Jorveza (budesonide orodispersible tablets) to be included on the BNSSG Adult Joint Formulary as TLS Amber 3 Months for maintenance treatment of eosinophilic oesophagitis once a shared care protocol has been developed and approved. 

Guanfacine for ADHD to be included on the BNSSG Adult Joint Formulary as TLS Amber 3 months once a shared care protocol has been developed and approved. To be included as TLS Red in the interim. 

Cefazolin for treatment of susceptible MSSA infections where flucloxacillin is not suitable due to intolerance or adverse effects to be included on the Formulary as TLS Red, restricted to use on microbiology advice only once directorate sign-off is confirmed. 

Dapsone tablets - for treatment of dermatoses and oral ulceration.  Further information required for Joint Formulary Group to assess application.